Pharmaceutical industry – Page 31
-
BusinessJudge voids Merck & Co’s $200m patent claim
‘Serious misconduct’ kills case over Gilead’s hepatitis C drugs
-
BusinessAdventures of an accidental entrepreneur
India needs to break out of its colonial mindset and tap into its innovative potential, says Biocon chief Kiran Mazumdar-Shaw
-
Business
Merck & Co to buy Afferent for neurology drugs
Deal worth up to $1.25bn includes drug candidate for chronic coughs
-
ResearchConnections in flow
MIT’s Klavs Jensen tells us how his research ranges in size from a chip, to a fridge to a shipping container
-
BusinessJazz Pharma buy out Celator in $1.5bn deal
Deal centres on promising leukaemia drug fast-tracked by the US Food and Drug Administration
-
BusinessIndia hit hard by US regulatory sanctions
Data integrity issues have led to punitive measures, but companies are taking measures to improve
-
-
BusinessMylan expands in dermatology
$1bn deal with Renaissance Acquisition Holdings brings 25 products and builds on Meda merger portfolio
-
BusinessPfizer to buy Anacor for eczema ointment
$5.2bn deal will bolster pharma giant’s inflammation and immunology drugs portfolio
-
-
BusinessDaiichi Sankyo awarded damages from former Ranbaxy owners
Arbitration says Singh family withheld information about regulatory investigations during Ranbaxy takeover
-
BusinessAbbot boosts heart devices with St Jude buyout
Medical devices consolidation continues with $25bn deal, but Abbott expresses concerns over proposed Alere merger
-
BusinessCancer deals spread
AbbVie nabs antibody specialist Stemcentrx, while Sanofi pursues Medivation
-
BusinessFDA moves to withdraw swine drug carbadox
Carcinogenic antibiotic has been banned in EU, Canada and Australia for years
-
BusinessUS treasury rules scupper Pfizer–Allergan merger
Government aims to crack down on corporate tax avoidance through ‘inversion’ deals
-
OpinionThrowing things over the fence
Saying ‘That’s someone else’s problem’ is asking for trouble, says Derek Lowe
-
BusinessIndian whistleblower pushes for regulatory reform
Although denied a hearing by India’s supreme court, Dinesh Thakur wants to shake up pharmaceutical safety laws
-
BusinessRoche sketches out Blueprint collaboration
Drug discovery startup will contribute to cancer immunotherapy projects aimed at kinase enzymes
-
BusinessIndia bans 344 combination drugs
Manufacturers appeal to courts to allow continued sales of products the government deems risky
-
OpinionDrugs don’t grow on trees
The trope of companies profiteering from academic discoveries doesn’t bear much scrutiny, says Derek Lowe